News and Activities

As director of Moores Cancer Center and the principal investigator for the Cancer Center Support Grant funded by the National Cancer Institute (NCI), Dr Simeone recently joins the Board of Directors of the Association of American Cancer Institutes to lead and collaborate with fellow cancer center leaders to accelerate discovery, improve access to care, and strengthen the impact of academic cancer centers nationwide. The Association of American Cancer Institutes (AACI) represents over 100 premier academic and freestanding cancer centers in the United States and Canada.

Read more about the news here.

Read more about AACI here.

In a recent interview with the San Diego Business Journal, Dr. Diane Simeone spoke about San Diego’s unique role in advancing cancer care. She emphasizes not only the power of collaboration across research, clinical care, and industry, but also how Moores, the region’s only NCI-designated Comprehensive Cancer Center, is driving transformative progress in early detection, precision medicine, and access to clinical trials.

Read more about the interview here.

In a recent interview with ASCO, Dr. Simeone discussed her role as the Executive Committee Chair of the Pancreatic Cancer Early Detection (PRECEDE) Consortium, and the importance of interdisciplinary care for patients to improve cancer care and survival outcomes.

Read more about the interview here.

Moores Director Diane Simeone, MD, has been recognized for her leadership at Moores to advance cancer research, care, and early detection to improve patient outcomes for a healthier future in San Diego and beyond. 

Read the news here

UCSD Moores Cancer Center received a $1 million donation from Pfizer to support early cancer detection and prevention.

Read the news here

Dr. Simeone talks about her life story from a basketball champion to surgeon and leader in the 2025 issue of Discoveries, a UC San Diego Health Sciences magazine.

Read the interview here

November is Pancreatic Cancer Awareness month. Hear Dr. Simeone explain pancreatic cancer early detection and prevention at UCSD campus on FOX5 evening news

Dr. Simeone talks about her lifelong work on improving survival of Pancreatic Cancer patients with OC Talk Radio: Living Hope

As Dr. Simeone joined UCSD Moores Cancer Center (MCC) as its new director, MCC became the new headquarter for PRECEDE, a growing network of 56 partnered centers focusing on early detection of pancreatic cancer.

Read the Cancer Center news here

Read the SD Tribune news here

Dorothy Bush and Tricia Reilly of @BBRwellness speaks with Diane Simeone, MD about the critical need for early detection of pancreatic cancer. Please check out this great source of information about pancreatic risk, who should get genetic testing and screened, and learn about the PRECEDE study, which is an amazing resource for at-risk patients. 

Watch the video presentation at The Legacy Continues Gala on February 18, 2023.

What is PRECEDE?

The Pancreatic Cancer Early Detection (PRECEDE) Consortium is an international, multi-institutional collaborative group of experts to increase survival for pancreatic cancer patients by improving early detection, screening, risk modeling and prevention for those with a heritable risk for pancreatic cancer, through a novel model of collaboration and data sharing. PRECEDE’s mission is to transform the early detection and prevention of pancreatic cancer, with the aim of increasing the 5-year survival rate from 10% to 50% within the next 10 years. With 48 leading academic medical centers across the globe, PRECEDE has assembled the largest high-risk patient cohort, with longitudinal clinical data and biospecimen acquisition and tracking.

William was our first undergraduate researcher at UCSD. He helped a lot setting up the lab, taking care of mice, and running experiments. Congrats William!

Part of the lab gathered together to celebrate William's graduation with delicious sushi and matcha cake because his 21st birthday is also around the corner. Happy birthday Willam!